Biotinylated Anti-DXD&Exatecan Antibody, Mouse IgG1, Avitag™ (MALS verified)

Product Specifications

Background

Dxd (Exatecan ADC derivative) is a potent DNA topoisomerase I inhibitor with an IC50 of 0.31 uM for targeting ADCs (DS-8201A) . Dxd was cytotoxic to human tumor cell lines KPL-4, NCI-N87 and SK-BR, 3 and the IC50s of MDA-MB-468 was 1.43 NM-4.07 nM, while lgGADC (Dxd as payload) had no inhibitory effect on HER2 expression in the 4 cell lines. DS8201a (Dxd as payload) had a significant inhibitory effect on HER2-positive KPL-4 and NCI cell lines N87 and SK-BRwith IC50 values of 26.8, 25.4 and 6.7 ng/mL, respectively, but had no inhibitory effect on MDA MB-468 (IC50, > 10000 - mL) . HRP-anti-DXD-antibody is a conjugation product of HRP and anti-DXD-antibody. It can be used in PK, PD analysis and ELISA.

Structure Composition

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Immunogen

DXD

Conjugation

Unconjugated

Applications

ELISA

Dilution

ELISA 1-5000 ng/mL

Purity

Protein A purified / Protein G purified

Modification

Biotinylated

Storage Conditions

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution.

Notes

For research use only, not for use in diagnostic procedure.

Specificity

Specifically recognizes the target-DXD.

Applications Notes

Immobilized Human Her2, His Tag at 1 μg/mL, add Trastuzumab Deruxtecan in the 100% Human Serum and then add Biotinylated Anti-DXD&Exatecan Antibody, Mouse IgG1, Avitag at 0.05 μg/mL. Detection was performed using HRP-conjugated Streptavidin (QC tested) .